What is the price target for ABVX stock?
14 analysts have analysed ABVX and the average price target is 154.7 USD. This implies a price increase of 52.41% is expected in the next year compared to the current price of 101.5.
ABIVAX SA-ADR (ABVX) Forecast, Price Target & Analyst Ratings
NASDAQ:ABVX • US00370M1036
Current stock price
101.5 USD
-0.97 (-0.95%)
At close:
103.11 USD
+1.61 (+1.59%)
Pre-Market:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ABIVAX SA-ADR (ABVX).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$154.70
Upside
+ 52.41%
From current price of $101.50 to mean target of $154.70, Based on 14 analyst forecasts
Low
$76.74
Median
$164.85
High
$215.29
Price Target Revisions
1 Month
0.00%
3 Months
18.87%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for ABVX. The average price target is 154.7 USD. This implies a price increase of 52.41% is expected in the next year compared to the current price of 101.5.
The average price target has been revised upward by 18.87% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
ABVX was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about ABVX.
In the previous month the buy percentage consensus was at a similar level.
ABVX was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-24 | Barclays | Maintains | Overweight -> Overweight |
| 2026-03-16 | Jefferies | Initiate | Buy |
| 2026-02-25 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-24 | Wedbush | Initiate | Underperform |
| 2026-01-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-08 | BTIG | Maintains | Buy -> Buy |
| 2025-12-16 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-06 | Wolfe Research | Initiate | Outperform |
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-10-10 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-07 | BTIG | Maintains | Buy -> Buy |
| 2025-09-25 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-09 | BTIG | Reiterate | Buy -> Buy |
| 2025-07-29 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-23 | LifeSci Capital | Maintains | Outperform -> Outperform |
| 2025-07-23 | Guggenheim | Maintains | Buy -> Buy |
| 2025-07-23 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-07-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-04-30 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-18 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-01-10 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-12-04 | JMP Securities | Initiate | Market Outperform |
| 2024-07-29 | Laidlaw & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 0.22% | N/A 3,694.18% | N/A 50.46% | N/A 99.66% | N/A 52.13% | N/A 29.34% | N/A 42.23% | N/A 15.91% | |||||||||||
| EBITDA YoY % growth | -18.119M | N/A 66.28% | -14.057M -130.05% | -19.037M -35.43% | -33.216M -74.48% | -37.942M -14.23% | -42.404M -11.76% | -50.719M -19.61% | -126.669M -149.75% | -171.884M -35.70% | N/A -25.11% | N/A -10.20% | N/A 71.55% | N/A 523.73% | N/A 88.93% | N/A 75.58% | N/A 24.52% | N/A | N/A | |
| EBIT YoY % growth | -18.255M | -18.236M 0.10% | -14.15M 22.41% | -19.108M -35.04% | -33.296M -74.25% | -38.008M -14.15% | -42.56M -11.98% | -51.204M -20.31% | -127.376M -148.76% | -172.984M -35.81% | N/A -21.03% | N/A -6.52% | N/A 52.40% | N/A 184.62% | N/A 301.34% | N/A 102.11% | N/A 51.79% | N/A 61.39% | N/A 18.10% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A 81.03% | N/A -178.79% | N/A -88.59% | N/A -32.95% | N/A -11.97% | N/A 173.61% | N/A -259.69% | N/A 19.63% | N/A -6.86% | N/A -20.70% | N/A 81.52% | N/A -363.61% | N/A 235.95% | N/A -204.97% | N/A 26.18% | N/A 83.69% | N/A | N/A |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-1.13%
EPS Next 5 Year
-8.10%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
266.42%
Revenue Next 5 Year
171.60%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
16.00%
EBIT Next 5 Year
40.70%
ABIVAX SA-ADR / ABVX Forecast FAQ
What is the number of analysts for ABVX stock?
The number of analysts covering ABIVAX SA-ADR (ABVX) is 14.